ResMed Inc (RMD)

Number of days of payables

		Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Payables turnover		7.52	9.36	9.41	8.25	8.05	10.70	9.30	10.28	12.39	10.84	8.31	8.63	9.76	10.33	9.15	8.30	9.84	11.03	10.57	10.74
Number of days of payables	days	48.55	39.01	38.80	44.22	45.35	34.11	39.24	35.49	29.47	33.67	43.92	42.31	37.41	35.34	39.88	43.96	37.10	33.08	34.52	33.98

June 30, 2025 calculation

Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 7.52
= 48.55

The analysis of ResMed Inc.'s accounts payable period over the specified periods demonstrates some notable fluctuations. Starting from September 30, 2020, the number of days of payables was approximately 33.98 days, indicating the company’s initial efficiency in settling its obligations. Throughout the subsequent periods, there was a gradual increase, with the payable days reaching a peak of around 48.55 days as of June 30, 2025.

Specifically, the data shows that by December 31, 2020, the payable days slightly increased to approximately 34.52 days. A relatively stable pattern persisted into early 2021, with a slight decrease to 33.08 days by March 31, 2021. Between June 30, 2021, and September 30, 2021, there was a notable rise, with payable days reaching approximately 43.96 days, indicating a lengthening of the company's payment cycle. This upward trend continued into late 2021 and 2022, with the payable days peaking at 43.92 days by December 31, 2022.

In 2023, there was a reduction in payable days, falling to approximately 33.67 days on March 31, followed by fluctuations but generally remaining below the peak observed in late 2022. By June 30, 2023, the number of days of payables decreased further to approximately 29.47 days, suggesting an improvement or tightening of payment practices. However, in the subsequent periods, the payable days increased again, reaching about 45.35 days by June 30, 2024, and continuing at similar levels into late 2024 and early 2025.

Overall, the trend exhibits periods of both expansion and contraction in the company's payable cycle. The increase in payable days over extended periods may reflect strategic financial management practices such as extending payment terms to optimize cash flow or accommodate supplier negotiations. Conversely, the fluctuations might also be influenced by operational needs, supply chain conditions, or changes in the company's credit policies. The variability underscores the importance of monitoring the payable cycle as an indicator of liquidity management and operational efficiency within ResMed Inc.